Aspen Neuroscience Selected as a Finalist for the Phacilitate Biotech Innovation Award

Aspen Neuroscience was selected as a finalist for the Biotech Innovation Award at the Advanced Therapies Awards at Phacilitate Advanced Therapies Week.

social banner finalist biotech

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.